Public case informationLast updated
Ardelyx Investor Misrepresentation Class Action
Ardelyx · IBSRELA and XPHOZAH drugs · New Filing
About this case
A shareholder class action lawsuit was filed against Ardelyx alleging that the company made materially false and misleading statements concerning its IBSRELA and XPHOZAH drugs. The matter is a new filing, and its current procedural stage beyond filing is not specified.
Case overview
- Defendant company
- Ardelyx
- Product or service
- IBSRELA and XPHOZAH drugs
- Case status
- New Filing
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Participation information
Ardelyx Investor Case Inquiry
The firm invites individuals who purchased Ardelyx shares between January 13, 2025 and August 6, 2026 and experienced an investment loss to discuss their legal rights.
Contact Marshall P. Dees, Esq. by email at mdees@holzerlaw.com, by telephone at (888) 508-6832, or through the firm's website.
- Type
- Law Firm Signup
- Reported proof requirement
- Unclear
Sources
- Ardelyx Investor Misrepresentation Class Action
Eagle-Tribune ·